Stocks Health care LSTA
NASDAQ · Health careLisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics, Inc. brought in $100K of revenue over the twelve months to June 30, 2026, down 90.7% from a year earlier. It posted a net loss of $14.6M. In fiscal 2024 capital spending exceeded operating cash flow by $16M. At June 30, 2026 it held $10.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Lisata Therapeutics, Inc.
- Net worth
- Lisata Therapeutics, Inc. has a market value (market cap) of $10.5M at the latest share price, and shareholders' equity of $8.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $170K (-83.0% year on year), with a net loss of $16.6M. Over the 12 months to June 30, 2026: revenue $100K, net loss $14.6M.
- Cash flow
- In fiscal 2024 operations used $15.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lisata Therapeutics, Inc.'s next report was expected around October 19, 2026 and is not on file with the SEC yet.
What Lisata Therapeutics, Inc. does
Lisata Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LSTA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $170K | -$16.6M | -$1.91 | -$16M |
| 2024 | $1M | -$20M | -$2.40 | -$19.4M |
| 2023 | $0 | -$20.8M | -$2.58 | -$20M |
| 2022 | $0 | -$54.2M | -$10.47 | -$21.5M |
| 2021 | n/a | -$27.5M | -$7.45 | -$22.3M |
| 2020 | n/a | -$8.2M | -$7.90 | -$8.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LSTA ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2014 | n/a | $0 | n/a |
| 2013 | n/a | $0 | n/a |
| 2012 | n/a | $327.7K | n/a |
| 2011 | n/a | $0 | n/a |
| 2011 | n/a | $222.9K | n/a |
Latest SEC filings
What Lisata Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026
- August 26, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 4, 2026
- July 28, 2026Tender offer (amended) SC TO-T/A
- July 24, 2026
- July 21, 2026Response to tender offer (amended) SC 14D9/A
- July 17, 2026
- July 17, 2026Response to tender offer (amended) SC 14D9/A
- July 17, 2026Tender offer (amended) SC TO-T/A
Insider trades
What the people running Lisata Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 9, 2026 | Klosk Steven MDirector | Received as pay | 30,456 | - |
| January 9, 2026 | Henson HeidiDirector | Received as pay | 30,456 | - |
| January 9, 2026 | Azab MohammadDirector | Received as pay | 30,456 | - |
| January 9, 2026 | Mazzo David JPresident & CEO, Director | Received as pay | 81,000 | - |
| January 9, 2026 | Mazzo David JPresident & CEO, Director | Shares withheld for tax | 10,503 | $20.7K |
| January 9, 2026 | Mazzo David JPresident & CEO, Director | Shares withheld for tax | 10,515 | $20.7K |
| January 9, 2026 | Mazzo David JPresident & CEO, Director | Shares withheld for tax | 12,224 | $24.1K |
| January 9, 2026 | Mazzo David JPresident & CEO, Director | Shares withheld for tax | 7,854 | $15.5K |
Who owns LSTA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Branham Justin Earl13G, passive | 5.1% | August 26, 2026 |
Largest institutional holders
Insiders
9 insiders reported holding 951,311 shares in total, about $1.1M at the last price.
| Holder | Shares |
|---|---|
| Mazzo David JPresident & CEO, Director | 311,890 |
| Azab MohammadDirector | 104,925 |
| Klosk Steven MDirector | 95,815 |
| Brown Gregory BDirector | 95,659 |
| Flowers Cynthia LouiseDirector | 95,446 |
| Buck Kristen KEVP, R&D and CMO | 93,462 |
| Henson HeidiDirector | 85,725 |
| Imam TariqSVP, Bus Dev, General Counsel | 36,078 |
| Nisco JamesSVP, Fin/Treas, Chief Actg Off | 32,311 |
Questions about LSTA
What does Lisata Therapeutics, Inc. do?
Lisata Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as LSTA. Its shares trade on NASDAQ under the ticker LSTA.
What is Lisata Therapeutics, Inc.'s net worth?
Lisata Therapeutics, Inc. has a market value (market cap) of $10.5M at the latest share price, and shareholders' equity of $8.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lisata Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.6M on revenue of $100K.
How much revenue does Lisata Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Lisata Therapeutics, Inc. reported revenue of $100K. That is 90.7% less than a year earlier.
When did Lisata Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 28, 2026.
When is Lisata Therapeutics, Inc.'s next earnings report?
Lisata Therapeutics, Inc.'s next report was expected around October 19, 2026 and is not on file with the SEC yet.
Similar companies
Compare LSTA with
Follow LSTA
Get an email when Lisata Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lisata Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.